Cargando…

Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors

In this review, we discuss biomarkers of response and resistance to PI3K inhibitors (PI3Ki) in estrogen receptor-positive breast cancer, both in the early and advanced settings. We analyse data regarding PIK3CA mutations, PI3K pathway activation, PTEN expression loss, Akt signalling, insulin levels,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brandão, M, Caparica, R, Eiger, D, de Azambuja, E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6923785/ https://www.ncbi.nlm.nih.gov/pubmed/31859350 http://dx.doi.org/10.1093/annonc/mdz280

Ejemplares similares

Biological characterization of SN32976, a selective inhibitor of PI3K and mTOR with preferential activity to PI3Kα, in comparison to established pan PI3K inhibitors
por: Rewcastle, Gordon W, et al.
Publicado: (2017)

PI3Kα Inhibitors That Inhibit Metastasis
por: Schmidt-Kittler, Oleg, et al.
Publicado: (2010)

Challenges in the clinical development of PI3K inhibitors
por: Massacesi, Cristian, et al.
Publicado: (2013)

PI3K inhibitors in inflammation, autoimmunity and cancer
por: Stark, Anne-Katrien, et al.
Publicado: (2015)

Phytochemicals and PI3K Inhibitors in Cancer—An Insight
por: Suvarna, Vasanti, et al.
Publicado: (2017)

PI3K inhibitors: review and new strategies
por: Zhang, Mingzhen, et al.
Publicado: (2020)

PI3K inhibitors in thrombosis and cardiovascular disease
por: Durrant, Tom N., et al.
Publicado: (2020)

Development and safety of PI3K inhibitors in cancer
por: Yu, Miaomiao, et al.
Publicado: (2023)

Efficacy of PI3K inhibitors in advanced breast cancer
por: Verret, B, et al.
Publicado: (2019)

Roles of PI3K pan-inhibitors and PI3K-δ inhibitors in allergic lung inflammation: a systematic review and meta-analysis
por: Kim, Jong Seung, et al.
Publicado: (2020)

Chromatin regulation at the intersection of estrogen receptor and PI3K pathways in breast cancer
por: Castel, Pau, et al.
Publicado: (2019)

Nexus between PI3K/AKT and Estrogen Receptor Signaling in Breast Cancer
por: Khatpe, Aditi S., et al.
Publicado: (2021)

Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib
por: Till, Kathleen J., et al.
Publicado: (2023)

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
por: Yahiaoui, Anella, et al.
Publicado: (2017)

Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
por: Akinleye, Akintunde, et al.
Publicado: (2013)

PI3K/Akt/mTOR inhibitors in breast cancer
por: Lee, Joycelyn JX, et al.
Publicado: (2015)

Structural Determinants of Isoform Selectivity in PI3K Inhibitors
por: Miller, Michelle S., et al.
Publicado: (2019)

The present and future of PI3K inhibitors for cancer therapy
por: Castel, Pau, et al.
Publicado: (2021)

PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise
por: Bou Zeid, Naji, et al.
Publicado: (2023)

PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors
por: Lehmann, Brian D, et al.
Publicado: (2014)

Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor
por: Karimi, Leena, et al.
Publicado: (2023)

Combination effects of sorafenib with PI3K inhibitors under hypoxia in colorectal cancer
por: Bhatia, Dimple R, et al.
Publicado: (2016)

Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer
por: Yang, Wei, et al.
Publicado: (2018)

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome
por: Rao, V. Koneti, et al.
Publicado: (2023)

The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases
por: Banham-Hall, Edward, et al.
Publicado: (2012)

Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer
por: Weigelt, Britta, et al.
Publicado: (2012)

Buparlisib is a brain penetrable pan-PI3K inhibitor
por: de Gooijer, Mark C., et al.
Publicado: (2018)

Suppression of insulin feedback enhances the efficacy of PI3K inhibitors
por: Hopkins, Benjamin D., et al.
Publicado: (2018)

Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer
por: Hashemzadeh, Kamelia, et al.
Publicado: (2019)

A Review of PI3K Inhibitors in B-Cell Malignancies
por: Cannon, Laura, et al.
Publicado: (2019)

Management of toxicity to isoform α-specific PI3K inhibitors
por: Nunnery, S E, et al.
Publicado: (2019)

PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects
por: Mishra, Rosalin, et al.
Publicado: (2021)

Differential Effects of Phosphatidylinositol 4-Kinase (PI4K) and 3-Kinase (PI3K) Inhibitors on Stomatal Responses to Environmental Signals
por: Takahashi, Sho, et al.
Publicado: (2017)

ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors
por: Rehman, Hasibur, et al.
Publicado: (2022)

Estrogen Receptor Signaling and the PI3K/Akt Pathway Are Involved in Betulinic Acid-Induced eNOS Activation
por: Hohmann, Nicolas, et al.
Publicado: (2016)

The Role of PI3K Inhibition in the Treatment of Breast Cancer, Alone or Combined With Immune Checkpoint Inhibitors
por: Zhang, Zhizhu, et al.
Publicado: (2021)

Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors
por: Nymark Aasen, Synnøve, et al.
Publicado: (2019)

RIDR-PI-103, ROS-activated prodrug PI3K inhibitor inhibits cell growth and impairs the PI3K/Akt pathway in BRAF and MEK inhibitor-resistant BRAF-mutant melanoma cells
por: Patel, Hima, et al.
Publicado: (2023)

Selection Study for B+- -> (K-+ pi+- pi-+ pi+-)D K+- and B+- -> (K+ K- pi+ pi-)D K+-".
por: Hunt, P, et al.
Publicado: (2009)

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances
por: Liu, Xiaochuan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pd6ofqdgrqrqlpgd3jr2bqqj17